Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation

American Journal of Cardiology

Volumn 111, Issue 2, 2013, Pages 219-224

  Sinner, Moritz F ^a,b,c   Wang, Na ^d   Fox, Caroline S ^b,e   Fontes, João D ^b   Rienstra, Michiel ^f   Magnani, Jared W ^b,g   Vasan, Ramachandran S ^b,g   Calderwood, Audrey H ^g   Pencina, Michael ^h   Sullivan, Lisa M ^d   Ellinor, Patrick T ^a   Benjamin, Emelia J ^b,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d BOSTON UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PR INTERVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SMOKING; SYSTOLIC BLOOD PRESSURE; VALVULAR HEART DISEASE;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; LIVER; MALE; MASSACHUSETTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSAMINASES;

EID: 84872045804     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.09.021     Document Type: Article

References (29)

1. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, and P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
2. L.A. Allen, G.M. Felker, S. Pocock, J.J. McMurray, M.A. Pfeffer, K. Swedberg, D. Wang, S. Yusuf, E.L. Michelson, C.B. Granger, and C. Investigators Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Eur J Heart Fail 11 2009 170 177
3. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, K.A. Ellenbogen, J.L. Halperin, J.Y. Le Heuzey, G.N. Kay, J.E. Lowe, S.B. Olsson, E.N. Prystowsky, J.L. Tamargo, S. Wann, S.C. Smith Jr., A.K. Jacobs, C.D. Adams, J.L. Anderson, E.M. Antman, S.A. Hunt, R. Nishimura, J.P. Ornato, R.L. Page, B. Riegel, S.G. Priori, J.J. Blanc, A. Budaj, A.J. Camm, V. Dean, J.W. Deckers, C. Despres, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, and J.L. Zamorano ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol 48 2006 854 906
4. U. Klotz Antiarrhythmics: elimination and dosage considerations in hepatic impairment Clin Pharmacokinet 46 2007 985 996
5. T.R. Dawber, G.F. Meadors, and F.E. Moore Jr. Epidemiological approaches to heart disease: the Framingham study Am J Public Health Nations Health 41 1951 279 281
6. American Gastroenterological Association American Gastroenterological Association medical position statement: evaluation of liver chemistry tests Gastroenterology 123 2002 1364 1366
7. R.B. Schnabel, L.M. Sullivan, D. Levy, M.J. Pencina, J.M. Massaro, R.B. D'Agostino Sr., C. Newton-Cheh, J.F. Yamamoto, J.W. Magnani, T.M. Tadros, W.B. Kannel, T.J. Wang, P.T. Ellinor, P.A. Wolf, R.S. Vasan, and E.J. Benjamin Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study Lancet 373 2009 739 745
8. K.K. Ho, K.M. Anderson, W.B. Kannel, W. Grossman, and D. Levy Survival after the onset of congestive heart failure in Framingham Heart Study subjects Circulation 88 1993 107 115
9. D.Y. Lin, L.J. Wei, and Z. Ying Checking the Cox model with cumulative sums of Martingale-based residuals Biometrika 80 1993 557 572
10. M.J. Pencina, and R.B. D'Agostino Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2004 2109 2123
11. R.B. D'Agostino, and B.H. Nam Evaluation of the performance of survival analysis models: discrimination and calibration measures N. Balakrishnan, C.R. Rao, Handbook of Statistics 2004 Elsevier Amsterdam, The Netherlands 1 25
12. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172
13. C. Labos, and K. Dasgupta Pancytopenia and atrial fibrillation associated with chronic hepatitis C infection and presumed hepatocellular carcinoma: a case report J Med Case Reports 2 2008 264
14. G.A. Makar, M.G. Weiner, S.E. Kimmel, D. Bennett, A. Burke, Y.X. Yang, X. Han, K. Sellers, L. Nessel, and J.D. Lewis Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population Pharmacoepidemiol Drug Saf 17 2008 43 51
15. M.C. Kew Serum aminotransferase concentration as evidence of hepatocellular damage Lancet 355 2000 591 592
16. R. Rej Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues Clin Chem 24 1978 1971 1979
17. V.M. van Deursen, K. Damman, H.L. Hillege, A.P. van Beek, D.J. van Veldhuisen, and A.A. Voors Abnormal liver function in relation to hemodynamic profile in heart failure patients J Card Fail 16 2010 84 90
18. W. Goessling, J.M. Massaro, R.S. Vasan, R.B. D'Agostino Sr., R.C. Ellison, and C.S. Fox Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease Gastroenterology 135 2008 1935 1944
19. H.J. Oh, T.H. Kim, Y.W. Sohn, Y.S. Kim, Y.R. Oh, E.Y. Cho, S.Y. Shim, S.R. Shin, A.L. Han, S.J. Yoon, and H.C. Kim Association of serum alanine aminotransferase and gamma-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease Korean J Hepatol 17 2011 27 36
20. M.F. Xia, H.M. Yan, H.D. Lin, H. Bian, B.S. Pan, X.Z. Yao, R.K. Li, M.S. Zeng, and X. Gao Elevation of liver enzymes within the normal limits and metabolic syndrome Clin Exp Pharmacol Physiol 38 2011 373 379
21. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 2002 1221 1231
22. J. Abramson, W.C. Hooper, D. Jones, S. Ashfaq, S. Rhodes, W. Weintraub, D. Harrison, A. Quyyumi, and V. Vaccarino Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease Atherosclerosis 178 2005 115 121
23. L.S. Bhatia, N.P. Curzen, P.C. Calder, and C.D. Byrne Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33 2012 1190 1200
24. B. Nalpas, A. Vassault, S. Charpin, B. Lacour, and P. Berthelot Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit Hepatology 6 1986 608 614
25. J.A. de Lemos, D.K. McGuire, and M.H. Drazner B-type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322
26. J.H. Henriksen, J.P. Gotze, S. Fuglsang, E. Christensen, F. Bendtsen, and S. Moller Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease Gut 52 2003 1511 1517
27. R.B. Schnabel, M.G. Larson, J.F. Yamamoto, L.M. Sullivan, M.J. Pencina, J.B. Meigs, G.H. Tofler, J. Selhub, P.F. Jacques, P.A. Wolf, J.W. Magnani, P.T. Ellinor, T.J. Wang, D. Levy, R.S. Vasan, and E.J. Benjamin Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community Circulation 121 2010 200 207
28. J.G. Smith, C. Newton-Cheh, P. Almgren, J. Struck, N.G. Morgenthaler, A. Bergmann, P.G. Platonov, B. Hedblad, G. Engstrom, T.J. Wang, and O. Melander Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation J Am Coll Cardiol 56 2010 1712 1719
29. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100